{"transactions":[{"id":1955179,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Restricted Stock Units","published_at":"2023-03-14T21:16:58.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":6298,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU represents a contingent right to receive one share of the Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":12596,"derivative":{"underlying":"Common Stock","underlying_shares":6298},"source":{"system":"sec-edgar","filing":"0001209191-23-018545","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018545/doc4.xml","form_type":"4"}},{"id":1955178,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-03-14T21:16:58.000Z","date":"2023-03-10","kind":"tax_withholding","acquired":false,"shares":2432,"price":6.52,"value":15856.64,"ownership":{"direct":true},"balance_after":18339,"source":{"system":"sec-edgar","filing":"0001209191-23-018545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018545/doc4.xml","form_type":"4"}},{"id":1955177,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-03-14T21:16:58.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":6298,"price":6.52,"value":41062.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The shares were received by the reporting person in connection with vesting of restricted stock units (\"RSUs\")."}],"balance_after":20771,"source":{"system":"sec-edgar","filing":"0001209191-23-018545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018545/doc4.xml","form_type":"4"}},{"id":1955176,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-03-14T21:16:58.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":1000,"price":6.5,"value":6500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."}],"balance_after":14473,"source":{"system":"sec-edgar","filing":"0001209191-23-018545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018545/doc4.xml","form_type":"4"}},{"id":1955175,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-03-14T21:16:58.000Z","date":"2023-03-07","kind":"purchase","acquired":true,"shares":2000,"price":7.044,"value":14088.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."}],"balance_after":13473,"source":{"system":"sec-edgar","filing":"0001209191-23-018545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018545/doc4.xml","form_type":"4"}},{"id":1955174,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-03-14T21:16:58.000Z","date":"2023-03-06","kind":"purchase","acquired":true,"shares":3000,"price":7.4845,"value":22453.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended."}],"balance_after":11473,"source":{"system":"sec-edgar","filing":"0001209191-23-018545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018545/doc4.xml","form_type":"4"}},{"id":2084255,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Restricted Stock Units","published_at":"2022-12-16T22:01:18.000Z","date":"2022-12-14","kind":"exercise","acquired":false,"shares":3100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":3100,"derivative":{"underlying":"Common Stock","underlying_shares":3100},"source":{"system":"sec-edgar","filing":"0001209191-22-061704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122061704/doc4.xml","form_type":"4"}},{"id":2084254,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2022-12-16T22:01:18.000Z","date":"2022-12-14","kind":"tax_withholding","acquired":false,"shares":1033,"price":17.23,"value":17798.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022."}],"balance_after":8009,"source":{"system":"sec-edgar","filing":"0001209191-22-061704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122061704/doc4.xml","form_type":"4"}},{"id":2084253,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2022-12-16T22:01:18.000Z","date":"2022-12-14","kind":"exercise","acquired":true,"shares":3100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were received by the Reporting Person in connection with vesting of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 278 shares acquired on January 31, 2022 and 1 share acquired on July 31, 2022, each under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended."}],"balance_after":9042,"source":{"system":"sec-edgar","filing":"0001209191-22-061704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122061704/doc4.xml","form_type":"4"}},{"id":2336247,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Restricted Stock Units","published_at":"2022-03-14T23:45:22.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":18894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."}],"balance_after":18894,"derivative":{"underlying":"Common Stock","underlying_shares":18894},"source":{"system":"sec-edgar","filing":"0001209191-22-018657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122018657/doc4.xml","form_type":"4"}},{"id":2336246,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T23:45:22.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":28341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the \"Company\") Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), will vest on the first anniversary of the March 10, 2022 grant date (the \"Grant Date\"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date."}],"balance_after":28341,"derivative":{"exercise_price":77.77,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":28341},"source":{"system":"sec-edgar","filing":"0001209191-22-018657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122018657/doc4.xml","form_type":"4"}},{"id":2470472,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":7944,"derivative":{"exercise_price":46,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":662},"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470471,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":1024,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":27.6,"expiration_date":"2027-12-15","underlying":"Common Stock","underlying_shares":1024},"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470470,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Restricted Stock Units","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-14","kind":"exercise","acquired":false,"shares":3100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\") vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\") vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":6200,"derivative":{"underlying":"Common Stock","underlying_shares":3100},"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470469,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":27,"price":180.6211,"value":4876.7697,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.47 to $180.81, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5663,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470468,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":206,"price":179.5781,"value":36993.0886,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.31 to $179.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5690,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470467,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":103,"price":178.9927,"value":18436.2481,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.29 to $179.26, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5896,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470466,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":223,"price":176.8253,"value":39432.0419,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $177.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5999,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470465,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":67,"price":175.8931,"value":11784.8377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.31 to $176.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6222,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470464,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":137,"price":174.6519,"value":23927.3103,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.03 to $175.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6289,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470463,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":91,"price":173.2926,"value":15769.6266,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.97 to $173.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6426,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470462,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":248,"price":172.3771,"value":42749.5208,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.97 to $172.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6517,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470461,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":254,"price":171.4693,"value":43553.2022,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.94 to $171.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6765,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470460,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":213,"price":170.4647,"value":36308.9811,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.78 to $170.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7019,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470459,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":117,"price":168.8217,"value":19752.1389,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.61 to $169.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7232,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470458,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":662,"price":46,"value":30452.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7349,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470457,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":1024,"price":27.6,"value":28262.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":6687,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470456,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-14","kind":"tax_withholding","acquired":false,"shares":1498,"price":168.43,"value":252308.14,"ownership":{"direct":true},"balance_after":5663,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2470455,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-16T22:15:45.000Z","date":"2021-12-14","kind":"exercise","acquired":true,"shares":3100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":7161,"source":{"system":"sec-edgar","filing":"0001209191-21-070012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070012/doc4.xml","form_type":"4"}},{"id":2479610,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"exercise","acquired":false,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":82500,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479609,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":100,"price":182.96,"value":18296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":4061,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479608,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":853,"price":182.2955,"value":155498.0615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.79 to $182.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4161,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479607,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":500,"price":180.294,"value":90147.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.92 to $180.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5014,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479606,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":500,"price":179.36,"value":89680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.89 to $179.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5514,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479605,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":500,"price":178.208,"value":89104.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.80 to $178.37, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6014,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479604,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":800,"price":176.195,"value":140956.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.84 to $176.75, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6514,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479603,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":900,"price":175.1322,"value":157618.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.71 to $175.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7314,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479602,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":200,"price":173.135,"value":34627.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.64 to $173.63, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8214,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479601,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":200,"price":171.3,"value":34260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.04 to $171.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8414,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479600,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":400,"price":168.77,"value":67508.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.40 to $169.07, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8614,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479599,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":167.06,"value":50118.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.59 to $167.39, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":9014,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479598,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":165.7967,"value":49739.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.40 to $166.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":9314,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479597,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":164.7667,"value":49430.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.37 to $165.13, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":9614,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479596,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":200,"price":162.825,"value":32565.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.42 to $163.23, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":9914,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479595,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":161.6333,"value":48489.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.29 to $162.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10114,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479594,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":160.5233,"value":48156.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.24 to $160.94, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10414,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479593,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":158.4233,"value":47526.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.25 to $158.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10714,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479592,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":200,"price":157.02,"value":31404.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.71 to $157.33, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11014,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479591,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":300,"price":156.2433,"value":46872.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.69 to $156.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11214,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479590,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":100,"price":154.38,"value":15438.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":11514,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479589,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":397,"price":153.5286,"value":60950.8542,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.03 to $153.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11614,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479588,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":100,"price":151.85,"value":15185.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":12011,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479587,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":200,"price":150.295,"value":30059.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.90 to $150.69, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":12111,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2479586,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-09T22:20:27.000Z","date":"2021-12-07","kind":"exercise","acquired":true,"shares":8250,"price":19.08,"value":157410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":12311,"source":{"system":"sec-edgar","filing":"0001209191-21-068836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121068836/doc4.xml","form_type":"4"}},{"id":2489515,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"exercise","acquired":false,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":90750,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489514,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":100,"price":211.75,"value":21175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":4061,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489513,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":551,"price":210.5742,"value":116026.3842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.40 to $211.11, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4161,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489512,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":879,"price":209.8055,"value":184419.0345,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.40 to $210.31, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4712,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489511,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":1450,"price":208.7772,"value":302726.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.22 to $209.20, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5591,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489510,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":353,"price":207.1935,"value":73139.3055,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.84 to $207.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7041,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489509,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":439,"price":206.0645,"value":90462.3155,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.63 to $206.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7394,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489508,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":465,"price":203.7942,"value":94764.303,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.14 to $204.11, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7833,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489507,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":715,"price":202.366,"value":144691.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.00 to $202.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8298,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489506,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":338,"price":201.2272,"value":68014.7936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.98 to $201.59, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":9013,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489505,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":717,"price":200.4041,"value":143689.7397,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.92 to $200.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":9351,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489504,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":678,"price":199.2499,"value":135091.4322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.83 to $199.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10068,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489503,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":836,"price":198.1697,"value":165669.8692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.70 to $198.64, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10746,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489502,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":356,"price":197.3079,"value":70241.6124,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.69 to $197.65, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11582,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489501,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":518,"price":195.8687,"value":101459.9866,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.43 to $196.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11938,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489500,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":200,"price":194.615,"value":38923.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.27 to $194.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":12456,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489499,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":222,"price":192.5762,"value":42751.9164,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.41 to $192.855, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":12656,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489498,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":4,"price":191.29,"value":765.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":12878,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489497,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":121,"price":189.9787,"value":22987.4227,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.27 to $190.03, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":12882,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2489496,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-12-02T21:13:47.000Z","date":"2021-11-30","kind":"exercise","acquired":true,"shares":8250,"price":19.08,"value":157410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13003,"source":{"system":"sec-edgar","filing":"0001209191-21-067558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067558/doc4.xml","form_type":"4"}},{"id":2492424,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Appreciation Right","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"exercise","acquired":false,"shares":1377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"kind","element":"transactionCoding","label":"F9","text":"The reporting person received 692 shares of common stock upon the net exercise of 1,377 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"). The reporting person forfeited 38 shares of common stock underlying the stock appreciation rights representing the base value and 647 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 26, 2021 of $217.97."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":30296,"derivative":{"exercise_price":5.95,"expiration_date":"2029-09-26","underlying":"Common Stock","underlying_shares":1377},"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492423,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"exercise","acquired":false,"shares":2083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":45834,"derivative":{"exercise_price":5.95,"expiration_date":"2029-09-26","underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492422,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"tax_withholding","acquired":false,"shares":647,"price":217.97,"value":141026.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"kind","element":"transactionCoding","label":"F9","text":"The reporting person received 692 shares of common stock upon the net exercise of 1,377 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"). The reporting person forfeited 38 shares of common stock underlying the stock appreciation rights representing the base value and 647 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 26, 2021 of $217.97."}],"balance_after":4753,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492421,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"disposition_to_issuer","acquired":false,"shares":38,"price":217.97,"value":8282.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"kind","element":"transactionCoding","label":"F9","text":"The reporting person received 692 shares of common stock upon the net exercise of 1,377 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"). The reporting person forfeited 38 shares of common stock underlying the stock appreciation rights representing the base value and 647 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 26, 2021 of $217.97."}],"balance_after":5400,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492420,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"exercise","acquired":true,"shares":1377,"price":5.95,"value":8193.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"kind","element":"transactionCoding","label":"F9","text":"The reporting person received 692 shares of common stock upon the net exercise of 1,377 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"). The reporting person forfeited 38 shares of common stock underlying the stock appreciation rights representing the base value and 647 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 26, 2021 of $217.97."}],"balance_after":5438,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492419,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":114,"price":221.2429,"value":25221.6906,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.89 to $221.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4061,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492418,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":155,"price":220.2217,"value":34134.3635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.85 to $220.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4175,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492417,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":412,"price":219.2546,"value":90332.8952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.84 to $219.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492416,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":626,"price":218.2544,"value":136627.2544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.815 to $218.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4742,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492415,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":331,"price":217.3602,"value":71946.2262,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.82 to $217.81, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5368,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492414,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":260,"price":216.1873,"value":56208.698,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.76 to $216.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5699,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492413,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":185,"price":215.0036,"value":39775.666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.67 to $215.63, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5959,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2492412,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-30T22:06:55.000Z","date":"2021-11-26","kind":"exercise","acquired":true,"shares":2083,"price":5.95,"value":12393.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":6144,"source":{"system":"sec-edgar","filing":"0001209191-21-067151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067151/doc4.xml","form_type":"4"}},{"id":2496405,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"exercise","acquired":false,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Plan. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":99000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496404,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":200,"price":203.615,"value":40723.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.30 to $203.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4061,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496403,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":870,"price":202.646,"value":176302.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.04 to $203.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4261,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496402,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":722,"price":201.4786,"value":145467.5492,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.02 to $202.01, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5131,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496401,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":1600,"price":200.5544,"value":320887.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.01 to $200.97, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5853,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496400,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":1387,"price":199.5096,"value":276719.8152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.01 to $199.99, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7453,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496399,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":1271,"price":198.4676,"value":252252.3196,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.00 to $198.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8840,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496398,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":1400,"price":197.4421,"value":276418.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.00 to $197.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10111,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496397,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":800,"price":196.4288,"value":157143.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.90 to $196.89, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11511,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2496396,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2021-11-24T22:21:27.000Z","date":"2021-11-23","kind":"exercise","acquired":true,"shares":8250,"price":19.08,"value":157410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":12311,"source":{"system":"sec-edgar","filing":"0001209191-21-066826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121066826/doc4.xml","form_type":"4"}},{"id":2508600,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-17T22:25:59.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":107250,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001209191-21-065181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121065181/doc4.xml","form_type":"4"}},{"id":2508599,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-17T22:25:59.000Z","date":"2021-11-15","kind":"exercise","acquired":false,"shares":662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":8606,"derivative":{"exercise_price":46,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":662},"source":{"system":"sec-edgar","filing":"0001209191-21-065181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121065181/doc4.xml","form_type":"4"}},{"id":2508598,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":115597,"kind":"person","name":"Glenn Gregory M","position":1,"cik":"0001342823","reported_name":"Glenn Gregory M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-17T22:25:59.000Z","date":"2021-11-15","kind":"exercise","acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":1024,"derivative":{"exercise_price":27.6,"expiration_date":"2027-12-15","underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001209191-21-065181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121065181/doc4.xml","form_type":"4"}}],"next_cursor":"2021-11-17T22:25:59.000000Z,2508598"}